Abstract
Before 21-st century, personalized medicine almost did not exist and treatment of every nosology considered the same methods and approaches, since it was impossible to resolve all of this by patient parameters. Nowadays, the main aspect of treatment depends on individualism of the patient, which itself depends on standard methods, however, it considers variability of parameters. Technological advances played a major role in this, it made genome sequencing possible, which has crucial benefits in terms of widely used drugs such as: anticoagulants, antivirals, NSAIDs etc. The margin between drugs effectiveness and toxicity is in direct correlation to several factors, for instance: age, sex, weight, concomitant diseases, etc. Nevertheless, for the development of personal medicine it is essential to apprise genetic polymorphism with all of the mentioned. Genetic polymorphism is vital in drug metabolism and its elimination and so in finding the boundary between toxicity and effectiveness, for the reason that it is through the determination of the genome that provides insight into the function of drug targets in each individual. By taking into account all of these and the knowledge in pharmacokinetics and pharmacodynamics, the effectiveness of treatment can be greatly increased, which is also confirmed by the modern methods used in the management of oncological diseases.
References
Archakov A., Aseev A., Bykov V., et al. Gene-centric view on the human proteome project: the example of the Russian roadmap for chromosome 18. Proteomics 2011; 11(10):1853-1856.
Baltimore D. Our genome unveiled. Nature 2001; 409(6822): 814–816.
Corwin E.J. The concept of epigenetics and its role in the development of cardiovascular disease: commentary on «New and emerging theories of cardiovascular disease». Biol Res Nurs 2004; 6(1):11–16, 21–23.
DeGoma E.M., Rivera G., Lilly S.M., et al. Personalized vascular medicine: individualizing drug therapy. Vascular Med 2011; 16(5):391-404.
Devaskar S.U., Thamotharan M. Metabolic programming in the pathogenesis of insulin resistance. Rev Endocr Metab Disord 2007; 8(2):105–113.
Evans WE, Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999, 286:487-491.
Fulle S., Centurione L., Mancinelli R., et al. Stem cell ageing and apoptosis. Curr Pharm 2012; 18(13):1694-1717. Scudellari M. Genomics contest underscores challenges of person- alized medicine. Nat Med 2012; 18(3):326
Futreal P.A., Coin L., Marshall M., et al. A census of human cancer genes. Nat Rev Cancer 2004; 4(3):177–183.
Ford L.T., Berg J.D. Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a phar- macogenomic test whose time has come. J Clin Pathol. 2010; 63(4):288-95.
Garber K. Human Cancer Genome Project moving forward despite some doubts in community. J Nat Cancer Inst 2005; 97(18):1322–24.
Goetz MP, Kamal A, Ames MM: Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther 2008, 83:160-166.
Golub T.R., Slonim D.K., Tamayo P., et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286(5439):531–37.
Hodgson D.R., Wellings R., Harbron C. Practical perspectives of personalized healthcare in oncology. N Biotechnol 2012; Mar 15. (Epub ahead of print).
I.I. Dedov 1 , A.N. Tyul’pakov 1 , V.P. Chekhonin 2 , V.P. Baklaushev 2 , A.I. Archakov 3 , S.A. Moshkovskii 3; Personalized medicine: State-of-the-art and prospects
Jain K.K. From molecular diagnostics to personalized medicine. Exp Rev Mol Diagn 2002; 2(4):299-301.
Jain K.K. Nanobiotechnology and personalized medicine. Prog Mol Biol Transl Sci 2011; 104:325-54.
Kaiser J. The Genome Project: What Will It Do as a Teenager? Sci-ence 2011; 331(6018):660.
Klein T.E., Altman R.B., Eriksson N., et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360(8):753–64.
Lander E.S., Linton L.M., Birren B., et al. Initial sequencing and analysis of the human genome. Nature 2001; 409(6822):860–921.
Lapuk A.V., Wu C., Wyatt A.W., et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol. 2012; 227(3):286-297.
Li and Jones Genome Medicine 2012, 4:27 Drug repositioning for personalized medicine.
Link E., Parish S., Armitage J., et al. SLCO1B1 variants and statin- induced myopathy: a genomewide study. N. Engl. J. Med 2008; 359(8):789–99.
McLeod HL, Siva C: The thiopurine S-methyltransferase gene locus -implications for clinical pharmacogenomics. Pharmacogenomics 2002, 3:89-98.
Peltonen L., McKusick V.A. Dissecting human disease in the post- genomic era. Science 2001; 291(5507):1224–29
Pene F., Courtine E., Cariou A., Mira J.P. Toward theranostics. Crit Care Med. 2009. 37:S50–S58.
Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies; frontiers in Pharmacology. Nat Med 2022;
Rajaraman P., Melin B.S., Wang Z., et al. Genome-wide association study of glioma and meta-analysis. Hum Genet. 2012 [Epub ahead of print]
Scudellari M. Genomics contest underscores challenges of personalized medicine. Nat Med 2012; 18(3):326.
Search Collaborative Group, Link E., Parish S., et al. SLCO1B1 variants and statin-induced myopathy – a genomewide study. N Engl J Med 2008; 359(8):789–799.
Sharom FJ: ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008, 9:105-127.
Sychev D.A., Batyukina S.V., Ostroumova O.D., et al. Personalization of Anticoagulant Therapy with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Chronic Kidney Disease Based on Pharmacogenetic Testing // Annals of the Russian academy of medical sciences. - 2023. - Vol. 78. - N. 2. - P. 120-131.
Thomson A. Why do therapeutic drug monitoring. The Pharm. Journal 2004; 273:153-155.
Van’t Veer L.J.,Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415(6871):530–36.
Worthey EA, Mayer AN, Syverson GD, Helbiling D, Bonacci BB,
Decker B, Serpe JM, Dasu T, Tschannen MR, Veith RL, Basehore MJ,
Broeckel U, Tomita-Mitchell, A, Arca MJ, Casper JT, Margolis DA, Bick DP,
Hessner MJ, Routes JM, Verbsky JW, Jacob HJ, Dimmock DP: Making a
definitive diagnosis: successful clinical application of whole exome
sequencing in a child with intractable inflammatory bowel disease.
Genet Med 2011, 13:255-262